QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:HZNP

Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

$68.41
+1.29 (+1.92%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$67.14
$69.03
50-Day Range
$66.96
$92.39
52-Week Range
$60.76
$120.54
Volume
2.75 million shs
Average Volume
2.07 million shs
Market Capitalization
$15.76 billion
P/E Ratio
21.11
Dividend Yield
N/A
Price Target
$117.22

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
71.4% Upside
$117.22 Price Target
Short Interest
Healthy
3.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
-0.20mentions of Horizon Therapeutics Public in the last 14 days
Based on 29 Articles This Week
Insider Trading
Selling Shares
$8.93 M Sold Last Quarter
Proj. Earnings Growth
26.77%
From $5.08 to $6.44 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.11 out of 5 stars

Medical Sector

9th out of 1,108 stocks

Pharmaceutical Preparations Industry

2nd out of 542 stocks

HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Horizon Therapeutics Public Price Performance

Shares of NASDAQ:HZNP traded down $2.53 during midday trading on Tuesday, reaching $67.12. 3,020,308 shares of the company traded hands, compared to its average volume of 2,062,524. The firm has a market cap of $15.46 billion, a PE ratio of 20.72, a PEG ratio of 1.46 and a beta of 1.12. The stock's 50-day simple moving average is $82.08 and its 200-day simple moving average is $93.13. Horizon Therapeutics Public has a 12 month low of $60.76 and a 12 month high of $120.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.79 and a current ratio of 4.05.

Horizon Therapeutics Public (NASDAQ:HZNP - Get Rating) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.36 by ($0.29). The company had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The firm's revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.62 earnings per share. As a group, equities analysts anticipate that Horizon Therapeutics Public will post 5.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HZNP has been the topic of several research analyst reports. The Goldman Sachs Group lowered their price objective on shares of Horizon Therapeutics Public from $164.00 to $144.00 and set a "buy" rating on the stock in a research note on Thursday, August 4th. UBS Group downgraded shares of Horizon Therapeutics Public from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $137.00 to $71.00 in a research note on Thursday, August 4th. SVB Leerink downgraded shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 4th. Oppenheimer restated a "buy" rating and issued a $140.00 price objective on shares of Horizon Therapeutics Public in a research note on Friday, July 8th. Finally, BMO Capital Markets lowered their price objective on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an "outperform" rating on the stock in a research note on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $117.22.

Insider Activity

In other news, CEO Timothy P. Walbert sold 17,600 shares of the firm's stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total value of $1,584,000.00. Following the completion of the sale, the chief executive officer now directly owns 460,549 shares in the company, valued at $41,449,410. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Timothy P. Walbert sold 25,000 shares of Horizon Therapeutics Public stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $92.48, for a total value of $2,312,000.00. Following the completion of the sale, the chief executive officer now directly owns 435,549 shares in the company, valued at $40,279,571.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Timothy P. Walbert sold 17,600 shares of Horizon Therapeutics Public stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total value of $1,584,000.00. Following the completion of the sale, the chief executive officer now owns 460,549 shares of the company's stock, valued at $41,449,410. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,384 shares of company stock worth $8,934,633. 2.50% of the stock is owned by corporate insiders.

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
8/03/2022
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
1,890
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$117.22
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+71.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$534.49 million
Pretax Margin
19.82%

Debt

Sales & Book Value

Annual Sales
$3.23 billion
Cash Flow
$6.33 per share
Book Value
$20.60 per share

Miscellaneous

Free Float
224,624,000
Market Cap
$15.76 billion
Optionable
Optionable
Beta
1.12

Social Links















HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HZNP shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2022?

8 brokerages have issued twelve-month price objectives for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they predict the company's stock price to reach $117.22 in the next twelve months. This suggests a possible upside of 73.9% from the stock's current price.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2022?

Horizon Therapeutics Public's stock was trading at $107.76 at the start of the year. Since then, HZNP stock has decreased by 37.5% and is now trading at $67.39.
View the best growth stocks for 2022 here
.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HZNP earnings forecast
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) posted its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by $0.29. The biopharmaceutical company had revenue of $876.40 million for the quarter, compared to analyst estimates of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a trailing twelve-month return on equity of 27.90%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.62 EPS.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.53 billion-$3.60 billion, compared to the consensus revenue estimate of $3.96 billion.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pictet Asset Management SA (0.97%), abrdn plc (0.91%), Allspring Global Investments Holdings LLC (0.73%), Congress Asset Management Co. MA (0.69%), Jennison Associates LLC (0.57%) and Tekla Capital Management LLC (0.38%). Insiders that own company stock include Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $67.39.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $15.53 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 1,890 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..
Read More

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.